VEGFA and age-related macular degeneration: Since 2004, anti‐VEGF agents have been the backbone treatment of many RDs, such as wet (i.e. with neovascularization) AMD and DME,[101] based on the fact that RDs exhibit VEGF‐mediated vascular proliferation and leakage.